CN111971387A - 新型透明质酸水解酶突变体和包含其的药物组合物 - Google Patents

新型透明质酸水解酶突变体和包含其的药物组合物 Download PDF

Info

Publication number
CN111971387A
CN111971387A CN201980023392.4A CN201980023392A CN111971387A CN 111971387 A CN111971387 A CN 111971387A CN 201980023392 A CN201980023392 A CN 201980023392A CN 111971387 A CN111971387 A CN 111971387A
Authority
CN
China
Prior art keywords
leu
lys
val
ala
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980023392.4A
Other languages
English (en)
Chinese (zh)
Inventor
朴淳宰
郑惠信
李承柱
柳善儿
宋炯楠
李昌禹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alteogen Inc
Original Assignee
Alteogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alteogen Inc filed Critical Alteogen Inc
Priority to CN202411133487.0A priority Critical patent/CN118755703A/zh
Priority to CN202411131388.9A priority patent/CN118773171A/zh
Priority to CN202411131157.8A priority patent/CN118853631A/zh
Priority to CN202411127100.0A priority patent/CN118792283A/zh
Publication of CN111971387A publication Critical patent/CN111971387A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Reproductive Health (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201980023392.4A 2018-07-25 2019-07-25 新型透明质酸水解酶突变体和包含其的药物组合物 Pending CN111971387A (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN202411133487.0A CN118755703A (zh) 2018-07-25 2019-07-25 新型透明质酸水解酶突变体和包含其的药物组合物
CN202411131388.9A CN118773171A (zh) 2018-07-25 2019-07-25 新型透明质酸水解酶突变体和包含其的药物组合物
CN202411131157.8A CN118853631A (zh) 2018-07-25 2019-07-25 新型透明质酸水解酶突变体和包含其的药物组合物
CN202411127100.0A CN118792283A (zh) 2018-07-25 2019-07-25 新型透明质酸水解酶突变体和包含其的药物组合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20180086308 2018-07-25
KR10-2018-0086308 2018-07-25
KR20190029758 2019-03-15
KR10-2019-0029758 2019-03-15
PCT/KR2019/009215 WO2020022791A1 (ko) 2018-07-25 2019-07-25 신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물

Related Child Applications (4)

Application Number Title Priority Date Filing Date
CN202411131157.8A Division CN118853631A (zh) 2018-07-25 2019-07-25 新型透明质酸水解酶突变体和包含其的药物组合物
CN202411131388.9A Division CN118773171A (zh) 2018-07-25 2019-07-25 新型透明质酸水解酶突变体和包含其的药物组合物
CN202411133487.0A Division CN118755703A (zh) 2018-07-25 2019-07-25 新型透明质酸水解酶突变体和包含其的药物组合物
CN202411127100.0A Division CN118792283A (zh) 2018-07-25 2019-07-25 新型透明质酸水解酶突变体和包含其的药物组合物

Publications (1)

Publication Number Publication Date
CN111971387A true CN111971387A (zh) 2020-11-20

Family

ID=69182377

Family Applications (5)

Application Number Title Priority Date Filing Date
CN201980023392.4A Pending CN111971387A (zh) 2018-07-25 2019-07-25 新型透明质酸水解酶突变体和包含其的药物组合物
CN202411131388.9A Pending CN118773171A (zh) 2018-07-25 2019-07-25 新型透明质酸水解酶突变体和包含其的药物组合物
CN202411127100.0A Pending CN118792283A (zh) 2018-07-25 2019-07-25 新型透明质酸水解酶突变体和包含其的药物组合物
CN202411133487.0A Pending CN118755703A (zh) 2018-07-25 2019-07-25 新型透明质酸水解酶突变体和包含其的药物组合物
CN202411131157.8A Pending CN118853631A (zh) 2018-07-25 2019-07-25 新型透明质酸水解酶突变体和包含其的药物组合物

Family Applications After (4)

Application Number Title Priority Date Filing Date
CN202411131388.9A Pending CN118773171A (zh) 2018-07-25 2019-07-25 新型透明质酸水解酶突变体和包含其的药物组合物
CN202411127100.0A Pending CN118792283A (zh) 2018-07-25 2019-07-25 新型透明质酸水解酶突变体和包含其的药物组合物
CN202411133487.0A Pending CN118755703A (zh) 2018-07-25 2019-07-25 新型透明质酸水解酶突变体和包含其的药物组合物
CN202411131157.8A Pending CN118853631A (zh) 2018-07-25 2019-07-25 新型透明质酸水解酶突变体和包含其的药物组合物

Country Status (11)

Country Link
US (2) US12371683B2 (enExample)
EP (1) EP3636752A4 (enExample)
JP (3) JP7204729B2 (enExample)
KR (3) KR20210023798A (enExample)
CN (5) CN111971387A (enExample)
AU (2) AU2019311658B2 (enExample)
BR (1) BR112020019041A2 (enExample)
CA (1) CA3093885A1 (enExample)
MX (1) MX2020009824A (enExample)
RU (1) RU2766680C1 (enExample)
WO (1) WO2020022791A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112203642A (zh) * 2019-03-25 2021-01-08 阿特根公司 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物
WO2023001264A1 (zh) 2021-07-23 2023-01-26 上海宝济药业有限公司 一种能皮下给药的抗生素药物组合物
US12221638B2 (en) 2020-08-07 2025-02-11 Alteogen Inc. Method for producing recombinant hyaluronidase
US12371683B2 (en) 2018-07-25 2025-07-29 Alteogen Inc. Hyaluronidase variants and pharmaceutical composition comprising the same

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2564103T3 (es) 2003-03-05 2016-03-17 Halozyme, Inc. Glicoproteína hialuronidasa soluble (sHASEGP), proceso para prepararla, usos y composiciones farmacéuticas que la comprenden
CN104244968B (zh) 2011-12-30 2017-07-25 哈洛齐梅公司 Ph20多肽变体、配制物及其应用
KR20210089215A (ko) 2018-11-07 2021-07-15 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항-pd-1 항체의 공동-제제
CN120699939A (zh) * 2020-01-23 2025-09-26 阿特根公司 具有改善的稳定性的新玻尿酸酶变体及含有其的药物组合物
US20220168403A1 (en) 2020-07-17 2022-06-02 Geron Corporation Subcutaneous telomerase inhibitor compositions and methods for using same
US20220089738A1 (en) * 2020-09-24 2022-03-24 Merck Sharp & Dohme Corp. Stable Formulations of Programmed Death Receptor 1 (PD-1) Antibodies and Hyaluronidase Variants and Fragments Thereof and Methods of Use Thereof
US20220233693A1 (en) 2020-12-28 2022-07-28 Bristol-Myers Squibb Company Antibody Compositions and Methods of Use Thereof
WO2022146948A1 (en) 2020-12-28 2022-07-07 Bristol-Myers Squibb Company Subcutaneous administration of pd1/pd-l1 antibodies
TW202305009A (zh) 2021-04-08 2023-02-01 美商默沙東有限責任公司 以皮下投予抗pd1抗體治療癌症之方法
CN117897172A (zh) 2021-08-02 2024-04-16 阿根思有限公司 皮下单位剂型
US20240392273A1 (en) 2021-09-14 2024-11-28 Takeda Pharmaceutical Company Limited Facilitated delivery of concentrated antibody formulations using hyaluronidase
EP4424301A4 (en) * 2021-10-29 2025-11-19 Alteogen Inc Pharmaceutical composition comprising a human PH20 hyaluronidase and a medicinal product
EP4469586A1 (en) 2022-03-01 2024-12-04 Exuma Biotech Corp. Viral particles with membrane-bound hyaluronidase
CN114573715A (zh) * 2022-03-14 2022-06-03 江苏雅酶医药科技有限公司 一种重组长效人透明质酸酶及其生产方法和应用
KR20230150203A (ko) 2022-04-20 2023-10-30 주식회사 알토스바이오로직스 오크렐리주맙(Ocrelizumab)을 포함하는 약학적 조성물과 그의 용도
JP2025518785A (ja) 2022-06-02 2025-06-19 ブリストル－マイヤーズ スクイブ カンパニー 抗体組成物及びその使用方法
KR102774438B1 (ko) * 2022-06-08 2025-02-27 (주)한국비엠아이 히알루로니다제 폴리펩티드 및 이의 용도
CN118401661A (zh) * 2022-06-22 2024-07-26 阿特根公司 N-末端和/或c-末端切割的可溶性ph20多肽及其用途
KR102621518B1 (ko) * 2022-06-29 2024-01-10 주식회사 오디스젠 중성 pH에서 활성을 나타내는 히알루로니다제 Hyal1변이체
JP2025523398A (ja) * 2022-06-29 2025-07-23 オディスジェン インコーポレイテッド 中性ｐＨで活性を示すヒアルロニダーゼＨＹＡＬ１変異体
EP4562048A1 (en) * 2022-07-28 2025-06-04 Merck Sharp & Dohme LLC Pharmaceutical compositions of programmed death receptor 1 (pd-1) antibodies and ph20 variants or fragments thereof
EP4562049A1 (en) * 2022-07-28 2025-06-04 Merck Sharp & Dohme LLC Pharmaceutical compositions of programmed death receptor 1 (pd-1) antibodies and rhuph20 or variants or fragments thereof
KR20240038901A (ko) * 2022-09-16 2024-03-26 (주)피앤피바이오팜 신규한 히알루로니다제 ph-20 변이체 및 그 용도
TW202440064A (zh) 2022-12-22 2024-10-16 美商哈洛賽恩公司 用於高容量施予之玻尿酸酶調製劑
WO2024196173A1 (ko) * 2023-03-23 2024-09-26 (주)알테오젠 신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물
KR20250086876A (ko) * 2023-12-06 2025-06-16 (주)한국비엠아이 히알루로니다제 폴리펩티드와 약물을 포함하는 피하투여용 조성물
WO2025136032A1 (ko) * 2023-12-21 2025-06-26 주식회사 오디스젠 개선된 특성을 갖는 히알루로니다제 hyal2 변이체
KR102875495B1 (ko) * 2023-12-28 2025-10-27 주식회사 오디스젠 히알루로니다제 Hyal1 변이체
CN119776311B (zh) * 2024-12-13 2025-12-19 江南大学 一种透明质酸合酶突变体及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100143457A1 (en) * 2008-12-09 2010-06-10 Ge Wei Extended soluble PH20 polypeptides and uses thereof
CN102065886A (zh) * 2008-04-14 2011-05-18 哈洛齐梅公司 修饰的透明质酸酶及其在治疗透明质酸相关疾病和病症中的应用
WO2013102144A2 (en) * 2011-12-30 2013-07-04 Halozyme, Inc. Ph20 polypeptede variants, formulations and uses thereof
US20150010529A1 (en) * 2013-07-03 2015-01-08 Ge Wei Thermally stable ph20 hyaluronidase variants and uses thereof
WO2016033555A1 (en) * 2014-08-28 2016-03-03 Halozyme, Inc. Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721348A (en) 1990-12-14 1998-02-24 University Of Connecticut DNA encoding PH-20 proteins
US5958750A (en) 1996-07-03 1999-09-28 Inctye Pharmaceuticals, Inc. Human hyaluronidase
US20090123367A1 (en) 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
ES2564103T3 (es) 2003-03-05 2016-03-17 Halozyme, Inc. Glicoproteína hialuronidasa soluble (sHASEGP), proceso para prepararla, usos y composiciones farmacéuticas que la comprenden
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
BRPI0618449A2 (pt) 2005-11-10 2011-08-30 Receptor Biologix Inc métodos para produção de isoformas de receptor e ligante
RU2471867C2 (ru) 2007-06-19 2013-01-10 Тамара П. Уваркина Гиалуронидаза и способ ее применения
ITMI20072225A1 (it) 2007-11-23 2009-05-24 Luso Farmaco Inst "composizioni farmaceutiche a base di antagonisti della bradichinina ed acido ialuronico e loro uso"
EP4269578B8 (en) 2008-03-06 2024-07-17 Halozyme, Inc. Soluble hyaluronidase composition
TWI532498B (zh) 2008-03-17 2016-05-11 巴克斯特保健公司 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
ES2573462T3 (es) 2008-12-09 2016-06-08 Halozyme, Inc. Polipéptidos de PH20 soluble extendida y usos de los mismos
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
WO2010138918A1 (en) 2009-05-29 2010-12-02 Pacira Pharmaceuticals, Inc. Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
CA2774053C (en) * 2009-09-17 2015-04-28 Baxter Healthcare, S.A. Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
AU2012236479B2 (en) 2011-03-31 2016-10-20 Merck Sharp & Dohme Llc Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments
NZ618331A (en) 2011-06-17 2016-04-29 Halozyme Inc Stable formulations of a hyaluronan-degrading enzyme
CN103173474B (zh) 2013-03-27 2014-08-27 广州白云山拜迪生物医药有限公司 一种用于cho细胞表达可溶性重组人透明质酸酶ph20的基因序列
JP6357363B2 (ja) 2013-06-26 2018-07-11 株式会社半導体エネルギー研究所 記憶装置
CA2930277A1 (en) 2013-11-13 2015-05-21 Tillotts Pharma Ag Multi-particulate drug delivery system
FI3083686T4 (fi) 2013-12-17 2023-05-09 Menetelmiä syöpien hoitamiseksi käyttäen pd-1-akselia sitovia antagonisteja ja taksaaneja
US20170218382A1 (en) 2014-07-31 2017-08-03 National University Corporation Kobe University Secretion Signal Peptide, And Protein Secretory Production And Cell Surface Display Using Said Secretion Signal Peptide
EA201700181A1 (ru) 2014-10-14 2017-09-29 Галозим, Инк. Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
CN104745553B (zh) 2015-03-27 2017-11-28 杭州北斗生物技术有限公司 重组人透明质酸酶及其制备方法和采用聚乙二醇共价修饰的化合物和方法
CA2896038C (en) 2015-07-03 2022-08-09 Glycobiosciences Inc. Polymer matrix compositions comprising a high concentration of bio-fermented sodium hyaluronate and uses thereof
US9995753B2 (en) 2015-09-25 2018-06-12 Merck Sharp & Dohme Corp. Anti-pembrolizumab antibodies
PH12018500950B1 (en) 2015-11-03 2023-09-20 Janssen Biotech Inc Subcutaneous formulations of anti-cd38 antibodies and their uses
AR107483A1 (es) 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
CN105567606B (zh) 2016-03-02 2019-03-19 青岛海洋生物医药研究院股份有限公司 一种球形节杆菌及其产生的透明质酸酶
JP2020500863A (ja) 2016-11-30 2020-01-16 メモリアル スローン ケタリング キャンサー センター 阻害剤官能化超小型ナノ粒子およびその方法
LT3589661T (lt) 2017-03-02 2024-02-12 Genentech, Inc. Adjuvantinis her2 atžvilgiu teigiamo krūties vėžio gydymas
SG10202110594UA (en) 2017-03-31 2021-11-29 Bristol Myers Squibb Co Methods of treating tumor
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US11723975B2 (en) 2017-05-30 2023-08-15 Bristol-Myers Squibb Company Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody
WO2019222435A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
AU2019311658B2 (en) 2018-07-25 2022-10-20 Alteogen, Inc Novel hyaluronidase variants and pharmaceutical composition comprising the same
BR112021016398A2 (pt) 2019-02-22 2021-11-23 Memorial Sloan Kettering Cancer Center Anticorpos cd33 e métodos de uso dos mesmos para tratar o câncer
CN121015892A (zh) 2019-03-25 2025-11-28 阿特根公司 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物
JP2020197994A (ja) 2019-06-04 2020-12-10 東芝テック株式会社 情報処理装置及びその制御プログラム
CN120699939A (zh) 2020-01-23 2025-09-26 阿特根公司 具有改善的稳定性的新玻尿酸酶变体及含有其的药物组合物
KR102649603B1 (ko) 2020-08-07 2024-03-21 (주)알테오젠 재조합 히알루로니다제의 생산 방법
US20220089738A1 (en) 2020-09-24 2022-03-24 Merck Sharp & Dohme Corp. Stable Formulations of Programmed Death Receptor 1 (PD-1) Antibodies and Hyaluronidase Variants and Fragments Thereof and Methods of Use Thereof
EP4424301A4 (en) 2021-10-29 2025-11-19 Alteogen Inc Pharmaceutical composition comprising a human PH20 hyaluronidase and a medicinal product

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102065886A (zh) * 2008-04-14 2011-05-18 哈洛齐梅公司 修饰的透明质酸酶及其在治疗透明质酸相关疾病和病症中的应用
KR20130116386A (ko) * 2008-04-14 2013-10-23 할로자임, 아이엔씨 히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도
US20100143457A1 (en) * 2008-12-09 2010-06-10 Ge Wei Extended soluble PH20 polypeptides and uses thereof
CN102307993A (zh) * 2008-12-09 2012-01-04 哈洛齐梅公司 延长的可溶性ph20多肽及其用途
WO2013102144A2 (en) * 2011-12-30 2013-07-04 Halozyme, Inc. Ph20 polypeptede variants, formulations and uses thereof
CN104244968A (zh) * 2011-12-30 2014-12-24 哈洛齐梅公司 Ph20多肽变体、配制物及其应用
US20150010529A1 (en) * 2013-07-03 2015-01-08 Ge Wei Thermally stable ph20 hyaluronidase variants and uses thereof
WO2015003167A1 (en) * 2013-07-03 2015-01-08 Halozyme, Inc. Thermally stable ph20 hyaluronidase variants and uses thereof
WO2016033555A1 (en) * 2014-08-28 2016-03-03 Halozyme, Inc. Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
US20170218069A1 (en) * 2014-08-28 2017-08-03 Halozyme, Inc. Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12371683B2 (en) 2018-07-25 2025-07-29 Alteogen Inc. Hyaluronidase variants and pharmaceutical composition comprising the same
CN112203642A (zh) * 2019-03-25 2021-01-08 阿特根公司 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物
CN116870164A (zh) * 2019-03-25 2023-10-13 阿特根公司 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物
CN116870164B (zh) * 2019-03-25 2024-07-23 阿特根公司 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物
CN112203642B (zh) * 2019-03-25 2025-03-07 阿特根公司 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物
US12221638B2 (en) 2020-08-07 2025-02-11 Alteogen Inc. Method for producing recombinant hyaluronidase
WO2023001264A1 (zh) 2021-07-23 2023-01-26 上海宝济药业有限公司 一种能皮下给药的抗生素药物组合物

Also Published As

Publication number Publication date
AU2023200324A1 (en) 2023-03-02
US12371683B2 (en) 2025-07-29
KR20210023798A (ko) 2021-03-04
EP3636752A4 (en) 2021-04-28
AU2019311658A8 (en) 2021-03-25
AU2019311658A1 (en) 2021-02-11
RU2766680C1 (ru) 2022-03-15
KR102151388B1 (ko) 2020-09-04
AU2023200324B2 (en) 2025-09-04
JP2025004002A (ja) 2025-01-14
CN118773171A (zh) 2024-10-15
AU2019311658B2 (en) 2022-10-20
CN118755703A (zh) 2024-10-11
CN118853631A (zh) 2024-10-29
JP2023052142A (ja) 2023-04-11
JP7204729B2 (ja) 2023-01-16
WO2020022791A1 (ko) 2020-01-30
MX2020009824A (es) 2021-01-15
KR20200017538A (ko) 2020-02-18
KR20250021616A (ko) 2025-02-13
US20250368976A1 (en) 2025-12-04
AU2023200324B9 (en) 2025-12-04
EP3636752A1 (en) 2020-04-15
US20210155913A1 (en) 2021-05-27
CA3093885A1 (en) 2020-01-30
JP2021507676A (ja) 2021-02-25
CN118792283A (zh) 2024-10-18
BR112020019041A2 (pt) 2021-02-09

Similar Documents

Publication Publication Date Title
AU2023200324B9 (en) Novel hyaluoronic acid-hydrolyzing enzyme variant and pharmaceutical composition containing same
KR102801434B1 (ko) 안정성이 향상된 신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물
US5827721A (en) BH55 hyaluronidase
US6123938A (en) Human urinary hyaluronidase
JP2002510462A (ja) 哺乳類のエンドグルクロニダーゼをコードする単離された核酸分子およびその使用
JP2003515338A (ja) 補体結合酵素、ｍａｓｐ−３、及びその使用
JP2002504376A (ja) ヒト血小板ヘパラナーゼポリペプチド、それをコードするポリヌクレオチド分子、およびヘパラナーゼ活性を改変する化合物の同定方法
US20250122492A1 (en) N-terminal and/or C-terminal Cleaved Soluble PH20 Polypeptide and Use Thereof
KR20250162568A (ko) 신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물
RU2811464C2 (ru) Новые варианты гиалуронидазы с улучшенной стабильностью и содержащая их фармацевтическая композиция
JPWO2002016610A1 (ja) 新規プロテアーゼ遺伝子

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20201120